Rigetti's Quantum Momentum Builds Despite Uneven Revenue Growth

Rigetti’s Q2 2026 revenue rose 185% year over year to $5.1 million, but two customers generated 80% of sales, including 64% from one customer. Operating expenses increased 48% to $30.3 million, R&D rose 53% to $20.7 million and the operating loss reached $28.1 million; liquidity was $541.3 million. The $8.4 million C-DAC system sale is expected to be recognized in Q4 2026 after installation and acceptance testing. RGTI shares were down 30.8% year to date, and the company had a Zacks Rank #5 (Strong Sell).

Analysis

The key distinction is revenue quality, not headline growth: project-based system sales can create sharp quarterly swings without establishing repeat demand. The C-DAC acceptance milestone is a near-term catalyst, but a successful delivery would validate execution more than recurring economics. The more consequential 1–3 month evidence is whether follow-on orders broaden the customer base and whether bookings convert on schedule. Concentration makes any delay disproportionately damaging to reported results; liquidity reduces immediate financing risk, not the risk that ongoing investment eventually requires dilution.

Over 6–18 months, quantum exposure may reward commercial distribution and funded roadmaps more than laboratory progress alone. IonQ’s enterprise-security channel offers a potential route to more diversified use cases, though the agreement’s ultimate revenue contribution and adoption remain unverified. D-Wave’s potential CHIPS support could lower funding pressure if awarded and received, but it does not resolve the margin and execution questions. SkyWater’s fabrication relationship with IonQ is a possible ecosystem read-through, not evidence yet of material earnings contribution.

Contrarian view: RGTI’s share-price underperformance may make the setup look washed out, but it does not cure customer concentration or prove commercial repeatability; avoid treating liquidity as a floor. A relative-value position favoring IONQ over RGTI is preferable to a broad quantum short, but remains exposed to high-beta sector repricing. The thesis weakens if Rigetti reports diversified repeat orders or if IonQ fails to convert its commercial pipeline into recognized revenue.

Key Decisions for Investors

• Consider a small, beta-aware long IONQ / short RGTI pair rather than an outright short of quantum computing: the wager is on relative commercial breadth, not a claim that IonQ’s agreement is already financially material. Reassess after the next reported conversion and customer-concentration data; cut the relative position if RGTI demonstrates repeat wins across multiple customers or IonQ’s bookings fail to translate into revenue.
• For RGTI, treat Q4 C-DAC installation and acceptance as a defined event, not a reason to buy ahead of recognition. Monitor acceptance timing, subsequent orders, and customer concentration; a delay or continued dependence on a few buyers would reinforce the downside thesis, while diversified follow-on contracts would falsify it.
• Keep QBTS as a watch item rather than buying on the headline funding amount: verify the final award, terms, and cash timing, then compare support against gross-margin and revenue conversion trends. Funding that is delayed or insufficient alongside continued margin weakness would undermine the bullish read-through.
• Do not trade SKYT on the IonQ fabrication news alone. Track whether the relationship expands into repeat production or meaningful disclosed orders before assigning an earnings benefit.